Founded in 2011, Invictus Oncology operates in Health Tech industry. Originally concentrating on R&D for innovative cancer treatments, the company has since evolved to provide personalized oncology so...
Funding stage:
Series A
Last funding:
07/02/2016
Total funding:
$1.88 Mn+
Revenue:
Investors
Employee count:
16
Last 90d
16
Last 90d
Glassdoor Rating:
Invictus Oncology: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders20
Latest Filing Date30 March 2023- Funding Events26
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Invictus Oncology
As of 31 March 2023, Invictus Oncology's equity is held by 18 shareholders, with the top three being Shiladitya Sengupta, Aarin Capital, and Navam Capital.
Shiladitya Sengupta holds the largest stake in Invictus Oncology at 29.6% as of 31 March 2023.
As of 31 March 2023, founders collectively hold 33.1% equity in Invictus Oncology.
As of 31 March 2023, investors collectively hold 48.1% equity in Invictus Oncology.
Invictus Oncology's ESOP pool stands at 17.6% of total equity as of 31 March 2023.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links